Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 14 studies | 45% ± 21% | |
peripheral blood | 13 studies | 25% ± 7% | |
lung | 11 studies | 24% ± 7% | |
eye | 6 studies | 35% ± 15% | |
kidney | 5 studies | 28% ± 7% | |
intestine | 4 studies | 23% ± 7% | |
uterus | 4 studies | 20% ± 3% | |
liver | 4 studies | 30% ± 11% | |
bone marrow | 3 studies | 21% ± 4% | |
heart | 3 studies | 34% ± 2% | |
lymph node | 3 studies | 33% ± 5% | |
breast | 3 studies | 17% ± 1% | |
adipose | 3 studies | 37% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 1780.58 | 258 / 258 | 100% | 15.38 | 230 / 230 |
breast | 100% | 2487.47 | 459 / 459 | 100% | 13.44 | 1118 / 1118 |
lung | 100% | 2126.54 | 578 / 578 | 100% | 9.47 | 1155 / 1155 |
ovary | 100% | 2239.49 | 180 / 180 | 100% | 6.85 | 430 / 430 |
prostate | 100% | 1884.00 | 245 / 245 | 100% | 17.20 | 502 / 502 |
uterus | 100% | 1476.89 | 170 / 170 | 100% | 10.40 | 459 / 459 |
esophagus | 100% | 1304.14 | 1443 / 1445 | 100% | 9.28 | 183 / 183 |
thymus | 100% | 1969.96 | 653 / 653 | 100% | 17.63 | 604 / 605 |
bladder | 100% | 1360.24 | 21 / 21 | 100% | 10.09 | 503 / 504 |
liver | 100% | 1177.62 | 226 / 226 | 100% | 7.54 | 405 / 406 |
pancreas | 100% | 849.81 | 327 / 328 | 100% | 10.99 | 178 / 178 |
kidney | 100% | 1466.25 | 89 / 89 | 99% | 10.91 | 896 / 901 |
stomach | 100% | 1178.69 | 359 / 359 | 99% | 10.92 | 284 / 286 |
brain | 99% | 1447.84 | 2622 / 2642 | 100% | 15.64 | 705 / 705 |
intestine | 100% | 1379.16 | 966 / 966 | 99% | 11.36 | 522 / 527 |
skin | 100% | 1446.37 | 1807 / 1809 | 98% | 11.51 | 463 / 472 |
adipose | 100% | 2688.80 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1995.96 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 14.00 | 29 / 29 |
spleen | 100% | 1639.96 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 9.94 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.61 | 1 / 1 |
muscle | 100% | 1325.39 | 799 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 1419.97 | 907 / 929 | 0% | 0 | 0 / 0 |
heart | 96% | 1154.77 | 825 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 93% | 7.26 | 74 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0000079 | Biological process | regulation of cyclin-dependent protein serine/threonine kinase activity |
GO_2000045 | Biological process | regulation of G1/S transition of mitotic cell cycle |
GO_0006367 | Biological process | transcription initiation at RNA polymerase II promoter |
GO_0050821 | Biological process | protein stabilization |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0070516 | Cellular component | CAK-ERCC2 complex |
GO_0000307 | Cellular component | cyclin-dependent protein kinase holoenzyme complex |
GO_0070985 | Cellular component | transcription factor TFIIK complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000439 | Cellular component | transcription factor TFIIH core complex |
GO_0005675 | Cellular component | transcription factor TFIIH holo complex |
GO_0005634 | Cellular component | nucleus |
GO_0016251 | Molecular function | RNA polymerase II general transcription initiation factor activity |
GO_0016538 | Molecular function | cyclin-dependent protein serine/threonine kinase regulator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CCNH |
Protein name | Cyclin H Cyclin-H (MO15-associated protein) (p34) (p37) Cyclin-H |
Synonyms | |
Description | FUNCTION: Regulates CDK7, the catalytic subunit of the CDK-activating kinase (CAK) enzymatic complex. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts. Involved in cell cycle control and in RNA transcription by RNA polymerase II. Its expression and activity are constant throughout the cell cycle. . FUNCTION: Regulates CDK7, the catalytic subunit of the CDK-activating kinase (CAK) enzymatic complex. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts. Involved in cell cycle control and in RNA transcription by RNA polymerase II. Its expression and activity are constant throughout the cell cycle. . FUNCTION: Regulates CDK7, the catalytic subunit of the CDK-activating kinase (CAK) enzymatic complex. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts. Involved in cell cycle control and in RNA transcription by RNA polymerase II. Its expression and activity are constant throughout the cell cycle. . FUNCTION: Regulates CDK7, the catalytic subunit of the CDK-activating kinase (CAK) enzymatic complex. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts. Involved in cell cycle control and in RNA transcription by RNA polymerase II. Its expression and activity are constant throughout the cell cycle. . |
Accessions | ENST00000508855.5 A0A2R8Y4K6 ENST00000504878.1 ENST00000256897.9 D6RG18 ENST00000646883.1 P51946 D6RHI7 ENST00000645953.1 A0A2R8YEM2 |